Sugi Predict

Sugi Predict / Compounds / SCHEMBL6417467

SCHEMBL6417467

SCHEMBL6417467

CC(=O)NC1CCC(CC(=O)O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 2/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ KMT2A Q03164 3/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ ANPEP P15144 1/20 0.41
▸ ENPEP Q07075 1/20 0.41
▸ KDM1A O60341 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ SLC6A1 P30531 2/20 0.38
▸ GABRA5 P31644 2/20 0.38
▸ GABRB2 P47870 2/20 0.38
▸ SLC6A12 P48065 2/20 0.38
▸ SLC6A11 P48066 2/20 0.38
▸ SLC6A13 Q9NSD5 2/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRR1 P24046 1/20 0.38
▸ GABRA4 P48169 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417470 1.00 DRD2 (0.43) DRD2DRD3KMT2AEPHX1HPGD
SCHEMBL15788648 1.00 DRD2 (0.43) DRD2DRD3KMT2AEPHX1HPGD
SCHEMBL24754676 0.89 EPHX1 (0.52) KMT2AEPHX1HPGDATMALDH1A1
SCHEMBL2742459 0.86 KMT2A (0.42) DRD2DRD3KMT2AEPHX1HPGD
SCHEMBL14495791 0.86 KMT2A (0.42) DRD2DRD3KMT2AEPHX1HPGD
SCHEMBL22091383 0.82 ATM (0.47) KMT2AATMKDM1AALDH1A1KDM4E
SCHEMBL1900736 0.81 KMT2A (0.57) DRD2DRD3KMT2AEPHX1HPGD
SCHEMBL11687711 0.81 DRD2 (0.50) DRD2DRD3KMT2AEPHX1HPGD
SCHEMBL17872719 0.81 EPHX1 (0.39) DRD2DRD3KMT2AEPHX1HPGD
SCHEMBL17872722 0.81 EPHX1 (0.39) DRD2DRD3KMT2AEPHX1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019016828-A1 NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N-{4-[2-[4-(2,3-DICHLOROPHENYL)PIPERAZINE-1-YL]ETHYL] CYCLOHEXYL}-N',N'-DIMETHYLUREA HYDROCHLORIDE AND POLYMORPHS THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2019-01-24 — — WO claimed
US-20210070708-A1 Pharmaceutically Active Compounds BERGENBIO ASA (NO) 2021-03-11 — — US disclosed
US-10766861-B2 Pharmaceutically active compounds BERGENBIO ASA (NO) 2020-09-08 — — US disclosed
US-10336702-B2 Pharmaceutically active compounds BERGENBIO ASA (NO) 2019-07-02 — — US disclosed
WO-2019016828-A1 NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N-{4-[2-[4-(2,3-DICHLOROPHENYL)PIPERAZINE-1-YL]ETHYL] CYCLOHEXYL}-N',N'-DIMETHYLUREA HYDROCHLORIDE AND POLYMORPHS THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2019-01-24 — — WO disclosed
WO-2019016828-A1 NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N-{4-[2-[4-(2,3-DICHLOROPHENYL)PIPERAZINE-1-YL]ETHYL] CYCLOHEXYL}-N',N'-DIMETHYLUREA HYDROCHLORIDE AND POLYMORPHS THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2019-01-24 — — WO disclosed
US-20180029985-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS BERGENBIO AS (NO) 2018-02-01 — — US disclosed
EP-2995617-B1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS SHANGHAI INST PHARMACEUTICAL IND (CN) 2018-01-31 — — EP disclosed
EP-3240784-A2 INHIBITORS OF AKT KINASE BerGenBio ASA (NO) 2017-11-08 — — EP disclosed
US-9550741-B2 Benzoisothiazole compounds and methods of treating schizophrenia SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2017-01-24 — — US disclosed
WO-2016102672-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS BERGENBIO AS (NO) 2016-06-30 — — WO disclosed
US-20160096811-A1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2016-04-07 — — US disclosed
EP-2995617-A1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS Shanghai Institute of Pharmaceutical Industry (CN) 2016-03-16 — — EP disclosed
US-20050065140-A1 Serotonine reuptake inhibitor SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2005-03-24 — — US disclosed
EP-1466901-A1 SEROTONINE REUPTAKE INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-10-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336702-B2 Pharmaceutically active compounds UGT2B7, CYP3A5, UGT1A1 DRD2 3660/4885DRD3 3841/4885KMT2A 4539/4885
US-20160096811-A1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS HTR3A, SLC6A3, HTR5A DRD2 10/4885DRD3 5/4885KMT2A 1374/4885
US-20050065140-A1 Serotonine reuptake inhibitor HTR1A, SLC6A4, SLC6A2 DRD2 79/4885DRD3 194/4885KMT2A 1358/4885
US-20210070708-A1 Pharmaceutically Active Compounds UGT2B7, CYP3A5, UGT1A1 DRD2 3724/4885DRD3 3974/4885KMT2A 4518/4885
US-10766861-B2 Pharmaceutically active compounds UGT2B7, CYP3A5, UGT1A1 DRD2 3724/4885DRD3 3974/4885KMT2A 4518/4885
US-20180029985-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS UGT2B7, CYP3A5, UGT1A1 DRD2 3660/4885DRD3 3841/4885KMT2A 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.